US8013166B2ExpiredUtilityPatentIndex 51
Preparation and use of aryl alkyl acid derivatives for the treatment of obesity

Assignee: BAYER HEALTHCARE LLCPriority: May 9, 2003Filed: Sep 5, 2008Granted: Sep 6, 2011
Est. expiryMay 9, 2023(expired)· nominal 20-yr term from priority
Inventors:SMITH ROGER A CAMPBELL ANN-MARIE COISH PHILIP DAI MIAO JENKINS SUSAN LOWE DEREK O'CONNOR STEPHEN J SU NING WANG GAN ZHANG MINGBAO ZHU LEI
A61P 9/00A61P 9/12A61P 9/10A61P 3/10A61P 3/06A61P 35/00A61P 3/04A61P 3/00A61P 19/06A61P 1/16A61P 15/00A61P 19/02A61P 11/00C07D 263/58C07D 277/42C07D 277/82C07D 277/58C07D 235/30C07D 417/12C07D 413/12C07D 405/12C07D 263/60A61K 31/50
PatentIndex Score
Cited by
References
Claims
Abstract

This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.
Claims

exact text as granted — not AI-modified
1. A compound of Formula (I) 
       
         
           
           
               
               
           
         
       
       wherein
 Q is O or S; 
 A is a linker selected from 
 
       
         
           
           
               
               
           
         
         
           wherein p is 1 or 2 
         
         and 
       
       
         
           
           
               
               
           
         
         
           wherein m is 0 and n is 1, 2, 3, or 4, 
           or 
           m is 1 and n is 1, 2, or 3, 
           and 
         
         wherein said linker is optionally substituted by one or two R 8  groups; 
         R 1  and R 2  are independently selected from hydrogen, halo, (C 1 -C 6 )alkyl, and (C 1 -C 6 )alkoxy; 
         R 3  is selected from
 hydrogen, 
 (C 1 -C 6 )alkyl optionally substituted by hydroxy, 
 and 
 phenyl optionally substituted with (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, or halo; 
 
         R 4  is selected from hydrogen, nitro, and (C 1 -C 6 )alkyl; 
         or 
         R 3  and R 4  may, when taken together with the carbon atoms to which they are attached, form a benzene ring optionally substituted with up to two substituents selected from
 halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, cyano, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )haloalkoxy, aminocarbonyl, (C 1 -C 6 )alkylaminocarbonyl, bis[(C 1 -C 6 )alkyl]aminocarbonyl, aminosulfonyl, (C 1 -C 6 )alkylaminosulfonyl, bis[(C 1 -C 6 )alkyl]aminosulfonyl, (C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylsulfonylamino, hydroxy-(C 2 -C 6 )alkylaminocarbonyl, 1-morpholinylcarbonyl, and 1-piperidinylcarbonyl, 
 and 
 when two of said benzene ring substituents are (C 1 -C 6 )alkyl and are attached to adjacent carbon atoms of the benzene ring, they may be joined together to form a 5-7-membered carbocyclic ring; 
 
         R 5  is hydrogen or (C 1 -C 6 )alkyl; 
         R 6  is hydrogen; 
         R 7  is hydrogen
 or 
 (C 1 -C 6 )alkyl optionally substituted with
 (C 1 -C 6 )alkoxy, 
 bis[(C 1 -C 3 )alkyl]amino 
 or 
 phenyl optionally substituted with halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, or cyano; 
 
 
         or 
         R 6  and R 7  are both (C 1 -C 6 )alkyl; 
         or 
         R 6  and R 7  may form, together with the carbon atom to which they are attached,
 a 3- to 5-membered carbocyclic ring, 
 
         or
 a 6-membered ring represented by 
 
       
       
         
           
           
               
               
           
         
         
           
             wherein W is CH 2 , C(CH 3 ) 2 , O, NR 9 , S, or SO 2 ; 
           
         
         R 8  is (C 1 -C 6 )alkyl; 
         and 
         R 9  is hydrogen or (C 1 -C 6 )alkyl; 
         or the pharmaceutically acceptable salts and esters thereof. 
       
     
     
       2. The compound of  claim 1 , wherein
 Q is O; 
 A is 
 
       
         
           
           
               
               
           
         
         
           wherein p is 1 or 2, 
         
         and 
         wherein said linker is optionally substituted by one or two R 8  groups; 
         R 3  and R 4  may, when taken together with the carbon atoms to which they are attached, form a benzene ring optionally substituted with up to two substituents selected from
 halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, cyano, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )haloalkoxy, aminocarbonyl, (C 1 -C 6 )alkylaminocarbonyl, bis[(C 1 -C 6 )alkyl]aminocarbonyl, aminosulfonyl, (C 1 -C 6 )alkylaminosulfonyl, bis[(C 1 -C 6 )alkyl]aminosulfonyl, (C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylsulfonylamino, hydroxy-(C 2 -C 6 )alkylaminocarbonyl, 1-morpholinylcarbonyl, and 1-piperidinylcarbonyl; and 
 
         R 1 , R 2 , R 6 , R 7 , R 8 , R 9 , and W are as defined in  claim 1 . 
       
     
     
       3. The compound of  claim 1 , wherein
 Q is O; 
 A is 
 
       
         
           
           
               
               
           
         
         
           wherein m is 0 and n is 1, 2, 3, or 4, 
           or 
           m is 1 and n is 1, 2, or 3, 
         
         and 
         wherein said linker is optionally substituted by one or two R 8  groups; 
         R 3  and R 4  may, when taken together with the carbon atoms to which they are attached, form a benzene ring optionally substituted with up to two substituents selected from
 halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, cyano, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )haloalkoxy, aminocarbonyl, (C 1 -C 6 )alkylaminocarbonyl, bis[(C 1 -C 6 )alkyl]aminocarbonyl, aminosulfonyl, (C 1 -C 6 )alkylaminosulfonyl, bis[(C 1 -C 6 )alkyl]aminosulfonyl, (C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylsulfonylamino, hydroxy-(C 2 -C 6 )alkylaminocarbonyl, 1-morpholinylcarbonyl, and 1-piperidinylcarbonyl; and 
 
         R 1 , R 2 , and R 8  are as defined in  claim 1 . 
       
     
     
       4. The compound of  claim 1 , wherein
 Q is S; 
 A is 
 
       
         
           
           
               
               
           
         
         
           wherein p is 1 or 2, 
         
         and 
         wherein said linker is optionally substituted by one or two R 8  groups; 
         R 3  and R 4  may, when taken together with the carbon atoms to which they are attached, form a benzene ring optionally substituted with up to two substituents selected from
 halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, cyano, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )haloalkoxy, aminocarbonyl, (C 1 -C 6 )alkylaminocarbonyl, bis[(C 1 -C 6 )alkyl]aminocarbonyl, aminosulfonyl, (C 1 -C 6 )alkylaminosulfonyl, bis[(C 1 -C 6 )alkyl]aminosulfonyl, (C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylsulfonylamino, hydroxy-(C 2 -C 6 )alkylaminocarbonyl, 1-morpholinylcarbonyl, and 1-piperidinylcarbonyl; and 
 
         R 1 , R 2 , R 6 , R 7 , R 8 , R 9 , and W are as defined in  claim 1 . 
       
     
     
       5. The compound of  claim 1 , wherein
 Q is S; 
 A is 
 
       
         
           
           
               
               
           
         
         
           wherein m is 0 and n is 1, 2, 3, or 4, 
           or 
           m is 1 and n is 1, 2, or 3, 
         
         and 
         wherein said linker is optionally substituted by one or two R 8  groups; 
         R 3  and R 4  may, when taken together with the carbon atoms to which they are attached, form a benzene ring optionally substituted with up to two substituents selected from
 halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, cyano, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )haloalkoxy, aminocarbonyl, (C 1 -C 6 )alkylaminocarbonyl, bis[(C 1 -C 6 )alkyl]aminocarbonyl, aminosulfonyl, (C 1 -C 6 )alkylaminosulfonyl, bis[(C 1 -C 6 )alkyl]aminosulfonyl, (C 1 -C 6 )alkylcarbonylamino, (C 1 -C 6 )alkylsulfonylamino, hydroxy-(C 2 -C 6 )alkylaminocarbonyl, 1-morpholinylcarbonyl, and 1-piperidinylcarbonyl; and 
 
         R 1 , R 2 , and R 8  are as defined in  claim 1 . 
       
     
     
       6. The compound of  claim 1  selected from the group consisting of:
 4-[4′-(1,3-benzoxazol-2-ylamino)-1,1′-biphenyl-4-yl]-4-oxo-2-(2-phenylethyl)butanoic acid; 
 2,2-dimethyl-4-{4′-[(6-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxobutanoic acid; 
 4-{4′-[(6-chloro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 4-{4′-[(6-methoxy-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 2,2-dimethyl-4-{4′-[(5-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxobutanoic acid; 
 2,2-dimethyl-4-{4′-[(4-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxobutanoic acid; 
 2,2-dimethyl-4-oxo-4-[4′-(5,6,7,8-tetrahydronaphtho[2,3-d][1,3]oxazol-2-ylamino)-1,1′-biphenyl-4-yl]butanoic acid; 
 4-{4′-[(5-fluoro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 4-{4′-[(5-isopropyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 2,2-dimethyl-4-oxo-4-{4′-[(5-propyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}butanoic acid; 
 trans-2-({4′-[(6-chloro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-methoxy-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(5-fluoro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(5,6-dimethyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-{[4′-(1,3-benzoxazol-2-ylamino)-1,1′-biphenyl-4-yl]carbonyl}cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(5-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(5-fluoro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)-cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(6-chloro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)-cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(6-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(5-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-[(4′-{[5-(trifluoromethyl)-1,3-benzoxazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(6-fluoro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)-cyclopentane-carboxylic acid; 
 trans-(1S,2S)-2-({4′-[(6-fluoro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)-cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclohexane-carboxylic acid; 
 trans-2-({4′-[(5-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclohexane-carboxylic acid; 
 4-{4′[(5-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxo-2-(2-phenylethyl) butanoic acid; 
 trans-2-({3′-fluoro-4′-[(6-methoxy-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-chloro-1,3-benzoxazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(6-fluoro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(5-fluoro-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(6-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(5-methyl-1,3-benzoxazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; and 
 trans-(1R,2R)-2-[(3′-fluoro-4′-{[5-(trifluoromethyl)-1,3-benzoxazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid. 
 
     
     
       7. The compound of  claim 1  selected from the group consisting of:
 4-[4′-(1,3-benzothiazol-2-ylamino)-1,1′-biphenyl-4-yl]-2,2-dimethyl-4-oxobutanoic acid; 
 4-{4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 4-{4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 2,2-dimethyl-4-oxo-4-[4′-(1,3-thiazol-2-ylamino)-1,1′-biphenyl-4-yl]butanoic acid; 
 4-[4′-(1,3-benzothiazol-2-ylamino)-1,1′-biphenyl-4-yl]-2-(2-methoxyethyl)-4-oxobutanoic acid; 
 4-{4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2-(2-methoxyethyl)-4-oxobutanoic acid; 
 4-{4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2-(2-methoxyethyl)-4-oxobutanoic acid; 
 trans-2-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclobutane-carboxylic acid; 
 trans-2-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 4-{4′-[(5-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 2,2-dimethyl-4-{4′-[(6-nitro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxobutanoic acid; 
 4-{4′-[(4-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 trans-(1R,2R)-2-{[4′-(1,3-benzothiazol-2-ylamino)-1,1′-biphenyl-4-yl]carbonyl}cyclopentane-carboxylic acid; 
 trans-2-{[4′-(1,3-benzothiazol-2-ylamino)-1,1′-biphenyl-4-yl]carbonyl}cyclopentane-carboxylic acid; 
 4-{4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxo-2-(2-phenylethyl)butanoic acid; 
 2-(2-{4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2-oxoethyl)pentanoic acid; 
 trans-2-({4′-[(5-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-nitro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(4-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 4-{4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2-[2-(dimethylamino) ethyl]-4-oxobutanoic acid; 
 2-[2-(dimethylamino)ethyl]-4-{4′-[(5-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxobutanoic acid; 
 2-[2-(dimethylamino)ethyl]-4-{4′-[(6-nitro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxobutanoic acid; 
 trans-2-({4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-methyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-ethoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-fluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1S,2S)-2-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 2,2-dimethyl-4-{4′-[(5-nitro-1,3-thiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-4-oxobutanoic acid; 
 4-(4′-{[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino}-1,1′-biphenyl-4-yl)-2,2-dimethyl-4-oxobutanoic acid; 
 trans-(1R,2R)-2-({4′-[(4,6-difluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1S,2S)-2-({4′-[(4,6-difluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 cis-3-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclohexane-carboxylic acid; 
 cis-3-({4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclohexane-carboxylic acid; 
 trans-2-[(4′-{[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(6-fluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(6-methyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1S,2S)-2-({4′-[(6-fluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1S,2S)-2-({4′-[(6-methyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(4,6-difluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(4-methyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(5-fluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-[(4′-{[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; 
 trans-2-({4′-[(5-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(5,7-dimethyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-[(4′-{[6-(methylsulfonyl)-1,3-benzothiazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; 
 trans-2-({4′-[(5,6-dimethyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 4-{4′-[(6-ethoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 4-{4′-[(6-fluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}-2,2-dimethyl-4-oxobutanoic acid; 
 trans-2-({4′-[(5,7-difluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopropane-carboxylic acid; 
 trans-(1R,2R)-2-[(4′-{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; 
 trans-2-{[4′-(1,3-benzothiazol-2-ylamino)-1,1′-biphenyl-4-yl]carbonyl}cyclopropane-carboxylic acid; 
 trans-2-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclohexane-carboxylic acid; 
 trans-2-({4′-[(4-methyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopropane-carboxylic acid; 
 trans-2-({4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopropane-carboxylic acid; 
 trans-2-({4′-[(5,7-difluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopropane-carboxylic acid; 
 trans-2-({4′-[(4,6-difluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopropane-carboxylic acid; 
 trans-2-{[4′-(1,3-benzothiazol-2-ylamino)-1,1′-biphenyl-4-yl]carbonyl}cyclobutane-carboxylic acid; 
 trans-2-({4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclobutane-carboxylic acid; 
 trans-2-({4′-[(4-methyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclobutane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(6-isopropyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({3′-fluoro-4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-{[4′-(1,3-benzothiazol-2-ylamino)-3′-fluoro-1,1′-biphenyl-4-yl]carbonyl}cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(4,6-difluoro-1,3-benzothiazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1S,2S)-2-({4′-[(4,6-difluoro-1,3-benzothiazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-[(3′-fluoro-4′-{[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(5-fluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(4-methyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(5-chloro-1,3-benzothiazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(6-fluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(6-methyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(5,7-dimethyl-1,3-benzothiazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-({4′-[(5,7-difluoro-1,3-benzothiazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-[(3′-fluoro-4′-{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; 
 trans-(1R,2R)-2-[(3′-fluoro-4′-{[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; 
 trans-2-({3′-fluoro-4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclobutane-carboxylic acid; 
 trans-2-{[4′-(1,3-benzothiazol-2-ylamino)-3′-fluoro-1,1′-biphenyl-4-yl]carbonyl}cyclobutane-carboxylic acid; 
 trans-2-{[4′-(1,3-benzothiazol-2-ylamino)-3′-fluoro-1,1′-biphenyl-4-yl]carbonyl}cyclopropane-carboxylic acid; 
 trans-2-({3′-fluoro-4′-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopropane-carboxylic acid; 
 trans-(1R,2R)-2-({3′-fluoro-4′-[(6-isopropyl-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-({3′-fluoro-4′-[(6-fluoro-1,3-benzothiazol-2-yl)amino]-1,1′-biphenyl-4-yl}carbonyl)cyclopentane-carboxylic acid; 
 trans-2-[(3′-fluoro-4′-{[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,1′-biphenyl-4-yl)carbonyl]cyclopentane-carboxylic acid; and 
 4-{4′-[(6-chloro-1,3-benzothiazol-2-yl)amino]-3′-fluoro-1,1′-biphenyl-4-yl}-4-oxo-2-(2-phenylethyl)butanoic acid. 
 
     
     
       8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt or ester, in combination with a pharmaceutically acceptable carrier. 
     
     
       9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt or ester thereof, in combination with a pharmaceutically acceptable carrier and one or more pharmaceutical agents. 
     
     
       10. The pharmaceutical composition of  claim 9 , wherein said pharmaceutical agent is an anti-obesity agent selected from the group consisting of β-3 agonists, CB-1 antagonists, neuropeptide Y5 inhibitors, appetite suppressants, and lipase inhibitors. 
     
     
       11. The pharmaceutical composition of  claim 9 , wherein said pharmaceutical agent is an agent for the treatment of diabetes selected from the group consisting of insulin, PPAR ligands, sulfonylurea drugs, α-glucosidase inhibitors, biguanides, PTP-1B inhibitors, DPP-IV inhibitors, 11-beta-HSD inhibitors, GLP-1, GIP, PACAP, and secretin. 
     
     
       12. The pharmaceutical composition of  claim 9 , wherein said pharmaceutical agent is an agent for the treatment of lipid disorders selected from the group consisting of HMG-CoA inhibitors, nicotinic acid, fatty acid lowering compounds, lipid lowering drugs, ACAT inhibitors, bile sequestrants, bile acid reuptake inhibitors, microsomal triglyceride transport inhibitors, and fibric acid derivatives. 
     
     
       13. The pharmaceutical composition of  claim 9 , wherein said pharmaceutical agent is an anti-hypertensive agent selected from the group consisting of β-blockers, calcium channel blockers, diuretics, renin inhibitors, ACE inhibitors, AT-1 receptor antagonists, ET receptor antagonists, and nitrates. 
     
     
       14. A method of treating obesity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of  claim 1 . 
     
     
       15. A method of inducing weight loss comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of  claim 1 . 
     
     
       16. A method of treating obesity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of  claim 1  in combination with one or more pharmaceutical agents. 
     
     
       17. The method of  claim 16 , wherein the compound and one or more pharmaceutical agents are administered as a single pharmaceutical dosage formulation. 
     
     
       18. A method of treating obesity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a composition of  claim 8 .
Cited by (0)

No later patents cite this yet.
References (0)

No backward citations on record.